small nucleolar RNA, C/D box 8Genealiases: RNU6C · mgU6-53
Q-omics provides the consensus-scored SNORD8 profile across patient tissues and cancer cell-line models. SNORD8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, SNORD8 is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, SNORD8 RNA expression shows 10,109 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight STAD, BLCA, and DLBC as cancer lineages where SNORD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD8 survival associations across molecular data types. SNORD8 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD8 RNA expression–survival associations across cancer types. High SNORD8 expression shows unfavorable associations in STAD, KIRP, DLBC, CESC and KIRC, but favorable associations in PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for SNORD8 RNA expression.
This table summarizes SNORD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD8 shows higher tumor expression in BLCA, LUSC, LUAD, COAD and KIRC. The BLCA box plot shows higher SNORD8 RNA expression in tumor versus normal tissue (log2 FC = +0.646, t-test p = .003).
This table shows molecular features associated with SNORD8 in patient tissues and cancer cell lines. In patient samples, SNORD8 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
